CSV January 31, 2023 through January 31, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
THIMEROSAL	SPECIFIC	*USP36–NF31*	5369	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TOPICAL AEROSOL	TESTS/*Alcohol Determination, Method II <611>*							*Analysis*: Change Determine the alcohol content of the sample thus prepared by the *Gas–Liquid Chromatographic Method* (see *Method II* in *Alcohol Determination* <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: Determine the alcohol content of the sample thus prepared by the *Gas Chromatographic Method* (see *Method II* in *Alcohol D*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ete rminat ion <611>), using methyl ethyl ketone as the internal standard in place of acetonitrile.
CARAWAY OIL	DEFINITION	*USP36–NF31*	1924	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3: Change It contains NMT 50.0% of *d* -carvone ($C_{10}H_{14}O$). to: It contains NLT 50.0% of *d* -carvone ($C_{10}H_{14}O$).
NORTRIPTYLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*First Supplement to USP36–NF31*	6027	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Acceptance criteria*: Change *Standard solution* to: *Sample solution*
FOSPHENYTOIN SODIUM INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
MINOCYCLINE	*Assay*	*USP36–NF31*	4378	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE TABLETS								*Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution*—Transfer 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Minocycline Hydrochloride. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
HYDROGENATED POLYDECENE	ASSAY/*Content of Decene Oligomer*	*USP36–NF31*	2133	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *System suitability*: Change [Note—The retention time for squalene is about 18 min; the relative retention times for tetradecane, hexadecane,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and squalene are about 0.5, 0.6, and 1.0, respectively.] to: [Note—The retention time for squalane is about 18 min; the relative retention times for tetradecane, hexadecane, and squalane are about 0.5, 0.6, and 1.0, respectively.]
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM	ASSAY/ *Procedure*	*USP36–NF31*	3075	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Betamethasone dipropionate stock solution*: Change *J* being the ratio (in mg/g) of betamethasone to clotrimazole in the Cream to: *J* being the ratio of the labeled amount of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								betamethasone (in mg/g) to the labeled amount of clotrimazole (in mg/g) in the Cream
CALCIUM SULFATE	SPECIFIC TESTS/*Loss on Drying <731>*	*USP35–NF30*	1724	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Acceptance criteria*: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate
TAPIOCA STARCH	*Limit of oxidizing substances*	*USP35–NF30*	1987	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 8: Change Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodide color.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodine color.
LEVETIRACETAM	ADDITIONAL REQUIREMENTS	*USP35–NF30*	3659	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 9 of *USP Reference Standards* <*11*>: Change $C_8H_{14}ClNO_3$ 207.65 to: $C_8H_{15}ClN_2O_2$ 206.67
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution* <*711*>/ *Chromatographic system*	*Second Supplement to USP35–NF30*	5940	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Column*: Change 4.6-mm x 7.5-cm; 3-µm packing L7 to: 4.6-mm x 7.5-cm; 3- or 3.5-µm packing L7

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYMETELLOSE	IMPURITIES/*Chloride and Sulfate, Chloride <221>*	*USP36–NF31*	2044	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Change the subsection title *Standard solution* to: *Control solution* AND Line 4 of *Analysis*: Change *Standard solution* to: *Control solution* AND Line 2 of *Acceptance criteria*: Change *Standard solution* to: *Control solution*
BENZTROPINE MESYLATE	CHEMICAL INFORMATION	*USP36–NF31*	2628	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-, *endo*-, methanesulfonate; to: 8-Azabicyclo[3.2.1]octane, 3-(di

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phenylmethoxy)-*N*-methyl-, *endo*-, methane sulfonate;
LORAZEPAM TABLETS	IMPURITIES/*Organic Impurities/System suitability/Suitability requirements*	*USP36–NF31*	4153	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Tailing factor*: Change 2.0, *Standard solution* to: NMT 2.0, *Standard solution*
BRINZOLAMIDE	*Related compounds/Test 2*	*USP35–NF30*	2385	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 15 of *Procedure*: Change relative retention time greater than 6. to: relative retention greater than 6.
VINORELBINE INJECTION	*Assay*	*USP35–NF30*	5028	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Change *Phosphate buffer, Mobile phase,* and *System suitability solution* —Proceed as directed in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Assay under *Vinorelbine Tartrate*. to: *Phosphate buffer*—Dissolve 6.9 g of monobasic sodium phosphate in 900 mL of water. Adjust with phosphoric acid to a pH of 4.2, dilute with water to 1000 mL, and mix. *Mobile phase*—Dissolve 1.22 g of sodium 1-decan esulfonate in 620 mL of methanol. Add 380 mL of *Phosphate buffer*, mix, filter, and degas. Make adjustments if necessary (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								System Suitability under *Chromatography <621>*). *System suitability solution* —Dissolve accurately weighed quantities of USP Vinorelbine Tartrate RS and USP Vinorelbine Related Compound A RS in water, and dilute quantitatively, and stepwise if necessary, with water to obtain a solution having known concentrations of about 1.4 mg per mL and 0.01 mg per mL,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								respectively. Expose a portion of this solution in a suitable xenon lamp apparatus capable of supplying a dose of 1600 KJ/m^2 between 310 and 800 nm at a power of 500 W/m^2 for about 1 h, in order to generate an additional degradation product 3,6-epoxy vinorelbine having a relative retention time of about 0.8.
POWDERED BLACK PEPPER EXTRACT	DEFINITION	*USP36–NF31*	1365	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change It contains NLT 90.0% and NMT 110.0% of the labeled amount of piperine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: It contains NLT 90.0% and NMT 110.0% of the labeled amount of piperine, calculated on the dried basis.
POLYVINYL ACETATE PHTHALATE	IM PURITIES/*Free Phthalic Acid*	*USP36–NF31*	2168	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change 6 mg/mL of polyvinyl acetate to: 6 mg/mL of polyvinyl acetate phthalate
DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3263	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 6 of *Sample solution*: Change Pipet 1.0 mL of the sample solution to: Pipet 1.0 mL of the sample
IFOSFAMIDE	*Chloroform-*	*USP35–NF30*	3477	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 18 of *Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	insoluble phosphorus							*preparation*: Change ammonium hydroxide solution. to: ammonium hydroxide.
ATROPINE SULFATE TABLETS	*Assay*	*USP35–NF30*	2272	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 9 of *Procedure*: Change R_U and R_S are as defined therein. to: R_U and R_S are the peak area ratios of atropine to homatropine.
VANCOMYCIN INJECTION	SPECIFIC TESTS/ *Composition of Vancomycin*	*USP35–NF30*	5003	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 16 of *Analysis*: Change *D* = dilution factor, *Sample stock solution* to *Sample solution*, 25 to: *D* = dilution factor, *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								stock solution to *Sample solution* AND Line 29 of *Analysis*: Change *D* = dilution factor, *Sample stock solution* to *Sample solution*, 25 to: *D* = dilution factor, *Sample stock solution* to *Sample solution*
SUMATRIPTAN INJECTION	SPECIFIC TESTS/ *Osmolality and Osmolarity <785>*	*Second Supplement to USP35–NF30*	5996	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Change 270–330 mOsmol to: 270–330 mOsmol/kg
INOSITOL	SPECIFIC TESTS/ *Conductivity*	*USP36–NF31*	2049	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change Transfer 10.0 g of Inositol, weighed and calculated on the dried basis,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to a 50-mL volumetric flask, and dissolve in and dilute with water (previously boiled and cooled to room temperature) to volume. to: 0.2 g/mL of Inositol in water (previously boiled and cooled to room temperature).
CLONAZEPAM ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3053	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 6 of *Sample solution*: Change Pipet 2.5 mL of the *Sample solution* to: Pipet 2.5 mL of the sample
METHENAMINE ORAL SOLUTION	ASSAY/ *Procedure*	*USP36–NF31*	4288	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 10 of *Analysis*: Change *B*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								S = absorbance of the *Sample blank* to: B_S = absorbance of the *Standard blank*
AZITHROMYCIN	IMPURITIES/*Organic Impurities/Procedure 2*	*USP35–NF30*	2279	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 15 of *Analysis*: Change C_S = concentration of USP Azithromycin RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Azithromycin RS in the *Standard solution* (mg/mL) AND Add after C_U: P = potency of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATRACURIUM BESYLATE INJECTION	IMPURITIES/*Organic Impurities/Acceptance criteria/Table 2*	*Second Supplement to USP35–NF30*	5909	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Azithromycin RS (µg/mg of azithromycin) Footnote b: Change *cis* isomer of the hydroxy compound. to: *trans* isomer of the hydroxy compound. AND Footnote c: Change *trans* isomer of the hydroxy compound. to: *cis* isomer of the hydroxy compound. AND Footnote d: Change *cis* isomer of the monoacrylate. to: *trans* isomer of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monoacrylate. AND Footnote e: Change *trans* isomer of the monoacrylate. to: *cis* isomer of the monoacrylate.
ZINC SULFATE TABLETS	Identification/*B. Zinc*	*USP35–NF30*	5077	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sodium hydroxide solution*: Change 42 mg/mL of sodium hydroxide to: 420 mg/mL of sodium hydroxide
DIETHYL SEBACATE	DEFINITION	*USP36–NF31*	1994	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change Diethyl Sebacate consists of the diester of alcohol and sebacic acid. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diethyl Sebacate consists of the diester of alcohol (ethanol) and sebacic acid.
PROPYLENE GLYCOL MONOLAURATE	IM PURITIES/*Limit of Propylene Glycol*	*USP36–NF31*	2180	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 8 of *Analysis*: Change Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monocaprylate taken: to: Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monolaurate taken:
GLUCONOLACTONE	IDENTIFICATION/*A.*	*USP36–NF31*	3742	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 5 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change crystals of the phenylhydrazine of gluconic acid to: crystals of the phenylhydrazide of gluconic acid
METHOTREXATE	IMPURITIES/*Organic Impurities/Procedure 1: Related Compounds*	*USP35–NF30*	3855	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Footnote b of *Impurity Table 1*: Change (*S*)-2-{4-[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methylamino]-*N*-methylbenzamido}pentanedioic acid. to: (*S*)-2-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl](methyl)amino}benzamido)pentanedioic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid.
BETAMETHASONE ORAL SOLUTION	*Identification/A:*	*USP35–NF30*	2336	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Change A: to: A: *Thin-Layer Chromatographic Identification Test* <201>—
VINORELBINE INJECTION	*Related compounds*	*USP35–NF30*	5028	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Delete the subsection *Standard solution* and *Diluted standard solution*. Replace with: *Standard solution* —Dissolve an accurately weighed quantity of USP Vinorelbine Tartrate RS in *Mobile phase* to obtain a solution having a known concentration of about 1.4 mg per mL.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluted standard solution —Transfer 1.0 mL of the *Standard solution* to a 50-mL volumetric flask, and dilute with *Mobile phase* to volume. Pipet 1.0 mL of this solution into a 100-mL volumetric flask, and dilute with *Mobile phase* to volume. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the test for *Related compounds* under *Vinorelbine*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tartrate. to: Separately inject equal volumes (about 20 µL) of the *Test solution* and the *Diluted standard solution* into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Record the chromatograms for three times the retention time of the vinorelbine peak. Disregard any peaks with an area less than or equal to one-half of the area of the peak obtained for vinorelbine in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Diluted standard solution*. Calculate the percentage of each impurity in the portion of Injection taken by the formula: $100(r_i/r_s)$ in which r_i is the peak response for each impurity obtained from the *Test solution*; and r_s is the sum of the responses of all the peaks.
GOOD STORAGE AND DISTRIBUTION PRACTICES FOR DRUG PRODUCTS	QUALITY MANAGEMENT SYST EM/*Storage Management S ystem/Receivin g and Transferring Drug Products*	*USP36–NF31*	693	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of footnote 1: Change JP Edmond, to: JP Emond,
ACESULFAME POTASSIUM	IM PURITIES/*Limit*	*USP35–NF30*	1680	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to*	Line 25 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	of Fluoride						*USP36–NF31*	Change *C* = concentration of fluoride in the *Sample solution*, from the standard curve (mg/mL) to: *C* = concentration of fluoride in the *Sample solution*, from the standard curve (µg/mL)
AMANTADINE HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP35–NF30*	2153	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Chromatographic system*: Change Column: 0.32-mm × 30-cm, 0.25-?m film, phase G1 to: Column: 0.32-mm × 30-m, 0.25-?m film, phase G1
OXYBUTYNIN CHLORIDE EX	PERFORMANCE	*USP35–NF30*	4167	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to*	Line 3 of *Working*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TENDED-RELEASE TABLETS	TESTS/ *Dissolution <711>/Test 2*						*USP36–NF31*	*standard solution*: Change or transfer 10 mL for Tablets labeled to contain 10 mg, to a 100-mL volumetric flask. to: transfer 10 mL for Tablets labeled to contain 10 mg, or transfer 15 mL for Tablets labeled to contain 15 mg to a 100-mL volumetric flask.
ALLANTOIN	IDENTIFICATION	*First Supplement to USP35–NF30*	5429	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *B. Thin-Layer Chromatographic Identification Test <201>*: Change The R_F value of the principal spot from *Sample solution A* corresponds

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to that from *Standard solution A*, as described in the test for *Organic Impurities*. to: The R_F value of the principal spot from *Sample solution B* corresponds to that from *Standard solution A*, as described in the test for *Organic Impurities*.
CAPTOPRIL ORAL SUSPENSION	*Assay*	*USP35–NF30*	2477	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Mobile phase*: Change Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
CHROMATOGRAPHY	SYSTEMS UITABILITY/*Stationary Phase*	*USP35–NF30*	258	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Flow Rate (HPLC)*: Change ⊗ in which F_1 is the flow rate indicated in the monograph, in mL/min; F_2 is the adjusted flow rate, in mL/min; l_1 is the length of the column indicated in the monograph; l_2 is the length of the column used; d_1 is the column inner diameter indicated in the monograph; and d_2 is the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								internal diameter of the column used. Additionally, the flow rate can be adjusted by ±50%. to:  in which F_1 is the flow rate indicated in the monograph, in mL/min; F_2 is the adjusted flow rate, in mL/min; d_1 is the column inner diameter indicated in the monograph; and d_2 is the internal diameter of the column used. Additionally, the flow rate can be adjusted by ±50%.
LOW-SUBSTIT	*Assay*	*USP35–NF30*	1822	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
UTED HYDRO XYPROPYL CELLULOSE							*Supplement to USP36–NF31*	*Hypromellose 2906*, except to substitute *Low-Substituted Hydroxypropyl Cellulose for Hypromellose 2906* throughout. to: *Hypromellose*, except to substitute *Low-Substituted Hydroxypropyl Cellulose for Hypromellose* throughout.
NORGESTIMATE	*Limit of residual solvents*	*USP35–NF30*	4083	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Limit of residual solvents*: Change to: *Limit of residual solvents <467>*
VINCRISTINE SULFATE	IM PUR ITIES/*Organic Impurities*	*USP35–NF30*	5022	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change Result = $[r_{UA}/(?r_{UA}$ + 25*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{UB}$)] × 100 to: Result = [r_{UA}/(?r_{UA} + 30r_{UB})] × 100 AND Change line 12 of *Analysis*: Result = [?r_{UA}/(?r_{UA} + 25r_{UB})] × 100 to: Result = [?r_{UA}/(?r_{UA} + 30r_{UB})] × 100
ADAPALENE	IM PUR ITIES/*Residual Solvent: Limit of Triethylamine*	*Revision Bulletin (Official December 01, 2012)*	Online	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Diluent*: Change Dimethyl sulfoxide and 1 N sodium hydroxide solution (4:1) to: Dimethyl sulfoxide AND Line 1 of *Standard solution*: Change 3.2 ?g/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Triethylamine RS in *Diluent* to: 4.0 ?g/mL of USP Triethylamine RS in *Diluent*. Transfer 4.0 mL of this solution to a 20-mL headspace vial, and add 1.0 mL of 1 N NaOH solution. AND Line 1 of *Sample solution*: Change 40 mg/mL of Adapalene in *Diluent* to: 50 mg/mL of Adapalene in *Diluent*. Transfer 4.0 mL of this solution to a 20-mL headspace vial,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and add 1.0 mL of 1 N NaOH solution.
GLYCERYL BEHENATE	IMPURITIES	*USP35–NF30*	1811	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 34 of *Content of 1-Mono glycerides/Analysis*: Change *F* = equivalency factor of glyceryl monobehenate, 207.3 mg/mEq to: *F* = equivalency factor of glyceryl monobehenate, 0.2073 g/mEq AND Line 19 of *Limit of Free Glycerin/Analysis*: Change *F* = equivalency factor of glycerin, 23.0 mg/mEq to: *F* = equivalency

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								factor of glycerin, 0.023 g/mEq
CAPTOPRIL ORAL SOLUTION	*Assay*	*USP35–NF30*	2477	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Mobile phase*: Change Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid. to: Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
PHENYLALANINE	IMPURITIES	*USP35–NF30*	4296	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Heavy Metals, Method I <231>*: Change *Method I* to: *Method II*
ELEMENTAL I	*Drug*	*Second*	5633	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second*	Row 16 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MPURITIES--LIMITS	*Products/Large Volume Parenterals*	*Supplement to USP35–NF30*					*Supplement to USP36–NF31*	Column 4 of *Table 1*: Change 70 to: 100 AND Row 16 of Column 5 of *Table 1*: Change 25 to: 10

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Next page Next ›
- Last page Last »